News

News 2016-11-13T22:07:37+00:00

Arix Bioscience notes Artios Pharma’s new collaboration to develop inhibitors of novel cancer targets

LONDON, 12 June, 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or the “Company”), a global healthcare and life science company supporting medical innovation, is pleased to note the announcement by Artios Pharma Ltd, an Arix Bioscience Group Business, that it has signed a research collaboration and option agreement with Masaryk University (“MU”) in the Czech Republic for the development of novel cancer treatments targeting DNA [...]

June 12th, 2017|

Arix Bioscience notes the formation of Artios Pharma’s world-leading Scientific Advisory Board

Dr Simon Boulton – Senior Group Leader at the Francis Crick Institute and VP of Scientific Strategy at Artios Dr KJ Patel – tenured Principal Investigator at the Medical Research Council Laboratory of Molecular Biology at the University of Cambridge Dr Jos Jonkers – Professor of Molecular Experimental Oncogenetics and Cancer Therapeutics, and Head of Molecular Pathology at the Netherlands Cancer Institute Dr Serena Nik-Zainal – Cancer Research UK [...]

June 8th, 2017|

Arix Bioscience to present at Jefferies 2017 Global Healthcare Conference in New York

LONDON, 31 May, 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or “the Company”), a global healthcare and life science company supporting medical innovation, today announces that Joe Anderson, Chief Executive Officer of Arix Bioscience, will present at the Jefferies 2017 Global Healthcare Conference to be held on 6-8 June in New York, US. The presentation will be on Thursday, 8 June at 4pm EDT [...]

May 31st, 2017|

Arix Bioscience co-leads $45 million Series B investment round for Harpoon Therapeutics

- Funding to advance two of Harpoon’s immuno-oncology programmes into clinical trials - LONDON, 25 May, 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or “the Company”), a global healthcare and life science company supporting medical innovation, today announced that Harpoon Therapeutics, a new Arix Group Business, has closed a Series B investment round raising $45 million. Arix Bioscience co-led the financing round with New [...]

May 25th, 2017|

Arix Bioscience leads $65 million Series B investment round for Iterum

- Funding pivotal Phase 3 trial for novel antibiotic sulopenem - Investment in Ireland-based company focused on developing differentiated anti-infectives aimed at combatting pathogens LONDON, 19 May, 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or “the Company”), a global healthcare and life science company supporting medical innovation, today announced that Iterum, a new Arix Group Business, has closed a Series B investment round raising [...]

May 19th, 2017|

Arix Bioscience Notes Verona Pharma’s NASDAQ Global Market Listing and $80m Fundraise

LONDON, 28 April, 2017: Arix Bioscience plc (LSE: ARIX) (“Arix Bioscience” or “the Company”), a global healthcare and life science company supporting medical innovation, is pleased to note the announcement by Verona Pharma plc, an Arix Bioscience Group Business, that it has raised approximately $80.0 million before expenses in a successful NASDAQ listing. Verona’s global offering priced of an aggregate of 47,399,001 new ordinary shares, [...]

April 28th, 2017|

Maiden Annual Results 2016

London, UK, 28 April 2017: Arix Bioscience plc (LSE:ARIX) (“Arix Bioscience” or “the Company”), a global healthcare and life science company supporting medical innovation, today announces its maiden results for the period ended 31 December 2016. The following financial statements refer to the period in which Arix Bioscience was a private company, prior to its initial public offering on the Main Market of the London [...]

April 28th, 2017|

US FDA authorisation for Verona Pharma to proceed with clinical investigation of RPL554 with the acceptance of investigational new drug application

LONDON, 18 April, 2017: Arix Bioscience plc (LSE:ARIX) (“Arix Bioscience” or “the Company”), a global healthcare and life science company supporting medical innovation, is pleased to note the announcement today by Verona Pharma, in which it has a 6.6% holding, that it has received authorisation from the Food and Drug Administration to proceed with the first clinical trial of RPL554 in the US.   RPL554 [...]

April 18th, 2017|

Arix Bioscience plc, LDC and University of Leeds collaborate to develop novel therapeutics for metabolic diseases

First project from Arix’s agreement with LDC  LONDON, 20 MARCH 2017: Arix Bioscience plc (LSE:ARIX) (“Arix Bioscience” or “the Company”), a global healthcare and life science company supporting medical innovation, has signed an agreement with the Lead Discovery Center GmbH (LDC), Max Planck Innovation GmbH (MPI), and the University of Leeds to develop new therapeutics for metabolic diseases based on the discoveries from these organisations. [...]

March 20th, 2017|

Arix Bioscience plc signs strategic agreement with Takeda

LONDON, 2 MARCH 2017: Arix Bioscience plc (LSE:ARIX) (“Arix Bioscience” or “the Company”), a global healthcare and life science company supporting medical innovation, today announces a strategic agreement with Takeda Ventures, Inc. (“Takeda”). The agreement will maximise the complementary skills and experience of both Arix and Takeda across important therapeutic areas. The relationship brings together the unique combination of entrepreneurial business building, investing and industry [...]

March 20th, 2017|

ARIX BIOSCIENCE APPOINTS DR FRANZ B HUMER AS SENIOR INDEPENDENT DIRECTOR

LONDON, 31 OCTOBER 2016: Arix Bioscience plc (Arix Bioscience), a global healthcare and life science company supporting medical innovation, announced today that it had appointed Dr Franz B Humer as its Senior Independent Director. Dr Humer is one of the pharmaceutical industry’s most respected executives. He served as Chief Executive Officer and Chairman of Hoffmann-La Roche and Roche Holding AG over a period of 16 [...]

October 31st, 2016|

ARIX BIOSCIENCE SUPPORTS ARTIOS PHARMA, A NEW BIOTECH COMPANY FOCUSED ON DNA DAMAGE RESPONSE

LONDON, 21 SEPTEMBER 2016: Arix Bioscience PLC (Arix Bioscience), a global healthcare and life science company supporting medical innovation, announced today that it has participated, along with leading European and US healthcare investors, in a Series A financing of Artios Pharma Ltd., a new private company focused on the DNA Damage Response (DDR). Artios has announced the launch of the company, and successful completion of [...]

September 21st, 2016|

ARIX BIOSCIENCE SUPPORTS DEPIXUS, AN EARLY-STAGE COMPANY FOCUSED ON NUCLEIC ACID SEQUENCING & EPIGENETIC ANALYSIS

LONDON, JULY 25, 2016: Arix Bioscience Limited (Arix Bioscience), a global healthcare and life science company supporting medical innovation, announced today that it has provided equity capital to Depixus, an early-stage company, based in Paris, France that is developing novel technologies for combined genetic and epigenetic analysis. Arix Bioscience sources, finances and develops businesses addressing medical innovation at all stages of development. Edward Rayner, an [...]

July 26th, 2016|

ARIX BIOSCIENCE SUPPORTS INNOVATIVE RESPIRATORY DRUG COMPANY VERONA PHARMA PLC

Arix Bioscience is pleased to announce that it has participated along with renowned international healthcare investors in a placement with Verona Pharma plc, the drug development company focused on first-in-class medicines to treat respiratory diseases. Verona has announced publicly that it has successfully secured funding commitments to raise gross proceeds of approximately US$63.3 million through the placement. Verona's full announcement can be viewed here. The [...]

June 20th, 2016|

ARIX BIOSCIENCE HAS MADE $25 MILLION COMMITMENT TO LEADING THERAPEUTICS RESEARCH ACCELERATOR, BIOMOTIV

Media Release: Arix Bioscience Limited LONDON, APRIL 18, 2016: - Arix Bioscience Limited (Arix Bioscience), formerly Perceptive Bioscience Investments Limited, a global healthcare and life science company supporting medical innovation, announced today it has agreed to provide up to $25 million capital to BioMotiv LLC, a US-based therapeutic accelerator organisation providing access to pioneering science in leading universities. Arix Bioscience sources, finances and develops businesses [...]

April 18th, 2016|

ARIX SUPPORTS INNOVATIVE BIOPHARMA COMPANY, AUTOLUS

London, 3 March 2016 – ARIX SUPPORTS INNOVATIVE BIOPHARMA COMPANY, AUTOLUS Arix Bioscience, formerly Perceptive Bioscience Investments Ltd, has provided capital support to Autolus Limited (“Autolus”), a biopharmaceutical company focused on the development and commercialisation of next-generation engineered T-cell therapies for haematological and solid tumours. Alongside Woodford Investment Management LLP, the company has participated in a Series B financing round, providing £40 million of new capital to Autolus. Dr Joe Anderson, CEO of Arix Bioscience, said: ““We are delighted to be involved with a company with the potential to transform [...]

March 3rd, 2016|